Is GlobalFoundries On The Verge Of A Breakout?
GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…
Sell
36
ENTA Quote, Financials, Valuation and Earnings
Last price:
$5.89
Seasonality move
:
-2.91%
Day range:
$5.84 - $6.10
52-week range:
$4.09 - $17.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.00x
P/B ratio:
1.39x
Volume:
148.3K
Avg. volume:
194.2K
1-year change:
-51.32%
Market cap:
$129.8M
Revenue:
$67.6M
EPS (TTM):
-$4.54
Analysts' Opinion
-
Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.29, Enanta Pharmaceuticals has an estimated upside of 151.82% from its current price of $6.07.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $6.07.
Fair Value
-
According to the consensus of 4 analysts, Enanta Pharmaceuticals has 151.82% upside to fair value with a price target of $15.29 per share.
ENTA vs. S&P 500
-
Over the past 5 trading days, Enanta Pharmaceuticals has overperformed the S&P 500 by 15.6% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Enanta Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Enanta Pharmaceuticals revenues have been falling on a year-over-year basis for 15 quarters in a row. In the most recent quarter Enanta Pharmaceuticals reported revenues of $14.9M.
Earnings Growth
-
Enanta Pharmaceuticals earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Enanta Pharmaceuticals reported earnings per share of -$1.06.
Enterprise value:
-63.6M
EV / Invested capital:
-0.68x
Price / LTM sales:
2.00x
EV / EBIT:
--
EV / Revenue:
-0.99x
PEG ratio (5yr expected):
-0.50x
EV / Free cash flow:
0.77x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-25.91%
Net Income Margin (TTM):
-149.57%
Return On Equity:
-74.26%
Return On Invested Capital:
-74.26%
Operating Margin:
-164.32%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $81.2M | $72.9M | $64.5M | $17.1M | $14.9M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$129.1M | -$135.4M | -$102.1M | -$32.8M | -$24.5M | |
| EBITDA | -$122.7M | -$116.2M | -$87.1M | -$28.3M | -$21M | |
| Diluted EPS | -$5.98 | -$6.24 | -$4.54 | -$1.47 | -$1.06 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $428.2M | $341.9M | $271.1M | $351M | $242.9M | |
| Total Assets | $467.8M | $406.8M | $326.4M | $413.6M | $323M | |
| Current Liabilities | $26.6M | $30.7M | $32.2M | $54.6M | $45.9M | |
| Total Liabilities | $31.7M | $48.2M | $57.1M | $247.4M | $229.5M | |
| Total Equity | $436M | $358.6M | $269.4M | $166.1M | $93.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$94.6M | -$107.3M | -$55.5M | -$28.6M | -$13.5M | |
| Cash From Investing | $124.8M | -$88.4M | $77.3M | $58.6M | -$4.4M | |
| Cash From Financing | $5.3M | $186.1M | -$25.7M | -$6.4M | -$6.9M | |
| Free Cash Flow | -$101.8M | -$113.3M | -$82.2M | -$30.3M | -$16M | |
ENTA
Sector
Market Cap
$129.8M
$34.2M
Price % of 52-Week High
35.22%
43.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-51.32%
-41.71%
Beta (5-Year)
0.811
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.55
200-day SMA
Sell
Level
$8.42
Bollinger Bands (100)
Buy
Level
4.87 - 6.79
Chaikin Money Flow
Buy
Level
915.8K
20-day SMA
Buy
Level
$5.58
Relative Strength Index (RSI14)
Buy
Level
60.21
ADX Line
Buy
Level
18.43
Williams %R
Sell
Level
-12.6024
50-day SMA
Buy
Level
$5.60
MACD (12, 26)
Buy
Level
0.30
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Sell
Level
-1.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.6537)
Sell
CA Score
(Annual)
Level (-1.9553)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.6982)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Stock Forecast FAQ
In the current month, ENTA has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ENTA average analyst price target in the past 3 months is $15.29.
-
Where Will Enanta Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Enanta Pharmaceuticals share price will rise to $15.29 per share over the next 12 months.
-
What Do Analysts Say About Enanta Pharmaceuticals?
Analysts are divided on their view about Enanta Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Enanta Pharmaceuticals is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Enanta Pharmaceuticals's Price Target?
The price target for Enanta Pharmaceuticals over the next 1-year time period is forecast to be $15.29 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ENTA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Enanta Pharmaceuticals is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of ENTA?
You can purchase shares of Enanta Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Enanta Pharmaceuticals shares.
-
What Is The Enanta Pharmaceuticals Share Price Today?
Enanta Pharmaceuticals was last trading at $5.89 per share. This represents the most recent stock quote for Enanta Pharmaceuticals. Yesterday, Enanta Pharmaceuticals closed at $6.07 per share.
-
How To Buy Enanta Pharmaceuticals Stock Online?
In order to purchase Enanta Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Dick’s Sporting Goods Buying Foot Locker Smart?
Last week, Dick’s Sporting Goods (NYSE:DKS) announced that it would…
Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
55
RGC alert for May 21
Regencell Bioscience Holdings [RGC] is down 6.8% over the past day.
Buy
64
AKRO alert for May 21
Akero Therapeutics [AKRO] is up 0.59% over the past day.
Buy
76
AGYS alert for May 21
Agilysys [AGYS] is up 0.08% over the past day.
